Motilal Oswal remains bullish on Glenmark Pharma, citing a sharp earnings recovery, strong pipeline visibility, and improving financial metrics as key catalysts for potential upside in the stock.
Motilal Oswal remains bullish on Glenmark Pharma, citing a sharp earnings recovery, strong pipeline visibility, and improving financial metrics as key catalysts for potential upside in the stock.
<iframe src="https://hindustansphere.com/embed/cluster/2964df934bbea6bed0e8b5d1462ff6d6b24eec1d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Glenmark Pharma Profit Expected To Soar 5x in Two Years, Says Motilal Oswal — Check Target Price"></iframe>
